Abstract
The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Current Respiratory Medicine Reviews
Title:When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis
Volume: 9 Issue: 3
Author(s): Mili E. Torok
Affiliation:
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Abstract: The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Export Options
About this article
Cite this article as:
Torok E. Mili, When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990016
DOI https://dx.doi.org/10.2174/1573398X113099990016 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Neurosarcoidosis
Current Neuropharmacology Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews HIV-1, Methamphetamine and Astrocyte Glutamate Regulation: Combined Excitotoxic Implications for Neuro-AIDS
Current HIV Research Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study
Current HIV Research Nuclear Imaging of Inflammation in Neurologic and Psychiatric Disorders
Current Clinical Pharmacology Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Structure, Function and Control of Complement C5 and its Proteolytic Fragments
Current Molecular Medicine Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Polysaccharide Production in Pilot Scale Bioreactor Cultivations of Neisseria meningitidis Serogroup C
Current Biochemical Engineering (Discontinued) Role of Platelet Signaling in Thrombus Stabilization: Potential Therapeutic Implications
Current Signal Transduction Therapy Inhaled Dry Powder Formulations for Treating Tuberculosis
Current Drug Delivery Promises of Nanotechnology for Drug Delivery to Brain in Neurodegenerative Diseases
Current Nanoscience Effective Separation and Simultaneous Detection of Ceftriaxone Sodium and Levofloxacin in Human Urine by Capillary Zone Electrophoresis
Current Analytical Chemistry Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research HIV-1 Tat Disrupts CX3CL1-CX3CR1 Axis in Microglia via the NF-κBYY1 Pathway
Current HIV Research